Polycystic Ovarian Syndrome - Pipeline Review, H2 2016

Choose Licence

 

Polycystic Ovarian Syndrome - Pipeline Review, H2 2016 Summary Global Markets Directs, Polycystic Ovarian Syndrome - Pipeline Review, H2 2016?, provides an overview of the Polycystic Ovarian Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome - The report reviews pipeline therapeutics for Polycystic Ovarian Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Polycystic Ovarian Syndrome therapeutics and enlists all their major and minor projects - The report assesses Polycystic Ovarian Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Polycystic Ovarian Syndrome - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 

Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Polycystic Ovarian Syndrome Overview 7 Therapeutics Development 8 Pipeline Products for Polycystic Ovarian Syndrome - Overview 8 Pipeline Products for Polycystic Ovarian Syndrome - Comparative Analysis 9 Polycystic Ovarian Syndrome - Therapeutics under Development by Companies 10 Polycystic Ovarian Syndrome - Therapeutics under Investigation by Universities/Institutes 11 Polycystic Ovarian Syndrome - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Polycystic Ovarian Syndrome - Products under Development by Companies 16 Polycystic Ovarian Syndrome - Products under Investigation by Universities/Institutes 17 Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development 18 Addex Therapeutics Ltd 18 Crinetics Pharmaceuticals, Inc. 19 EffRx Pharmaceuticals S.A. 20 Euroscreen S.A. 21 Merck KGaA 22 Millendo Therapeutics, Inc. 23 Vicore Pharma AB 24 Polycystic Ovarian Syndrome - Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 C-21 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 choriogonadotropin alfa - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 ESN-364 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 JDSCR-004 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 KDT-501 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 metformin hydrochloride - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 MLE-4901 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 Polycystic Ovarian Syndrome - Dormant Projects 47 Polycystic Ovarian Syndrome - Discontinued Products 48 Polycystic Ovarian Syndrome - Product Development Milestones 49 Featured News & Press Releases 49 Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome 49 Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome 49 Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials 50 Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients 50 Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364 51 Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 51 Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome 51 Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364 52 Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations 52 Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 54 Disclaimer 55

List of Tables Number of Products under Development for Polycystic Ovarian Syndrome, H2 2016 8 Number of Products under Development for Polycystic Ovarian Syndrome - Comparative Analysis, H2 2016 9 Number of Products under Development by Companies, H2 2016 10 Number of Products under Investigation by Universities/Institutes, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Clinical Stage Development, H2 2016 13 Comparative Analysis by Early Stage Development, H2 2016 14 Comparative Analysis by Unknown Stage Development, H2 2016 15 Products under Development by Companies, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2016 18 Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals, Inc., H2 2016 19 Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals S.A., H2 2016 20 Polycystic Ovarian Syndrome - Pipeline by Euroscreen S.A., H2 2016 21 Polycystic Ovarian Syndrome - Pipeline by Merck KGaA, H2 2016 22 Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics, Inc., H2 2016 23 Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2016 24 Assessment by Monotherapy Products, H2 2016 25 Number of Products by Stage and Target, H2 2016 27 Number of Products by Stage and Mechanism of Action, H2 2016 29 Number of Products by Stage and Route of Administration, H2 2016 31 Number of Products by Stage and Molecule Type, H2 2016 33 Polycystic Ovarian Syndrome - Dormant Projects, H2 2016 47 Polycystic Ovarian Syndrome - Discontinued Products, H2 2016 48


Name*
Email ID*
Company*
Phone (With Country Code)*
What is/are your question(s)?:

Other Reports by Global Markets Direct

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017

Catenin Beta 1 (Beta Catenin or CTNNB1) - Pipeline Review, H2 2017 Summary Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 10 molecules are developed by companies and remaining b...

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017

Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017 Summary According to the recently published report 'Transthyretin (ATTR or Prealbumin or TBPA or TTR) - Pipeline Review, H2 2017'; Transthyretin (ATTR or Prealbumin or TBP...

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017

Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Pipeline Review, H2 2017 Summary Complement C5 (C3 And PZP Like Alpha 2 Macroglobulin Domain Containing Protein 4 or C5) - Complement component 5 is a protein...

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017

Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) - Pipeline Review, H2 2017 Summary Protein Kinase C Epsilon Type (nPKC Epsilon or PRKCE or EC 2.7.11.13) pipeline Target constitutes close to 7 molecules. Out of which approximat...

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017

Aurora Kinase C (Aurora 3 or Aurora/IPL1 Related Kinase 3 or Aurora/IPL1/Eg2 Protein 2 or Serine/Threonine Protein Kinase 13 or Serine/Threonine Protein Kinase Aurora C or AURKC or EC 2.7.11.1) - Pipeline Review, H2 2017 Summary According to the re...

New Pharmaceuticals and Healthcare Reports